Paclitaxel for Stage IV Ovarian Cancer
Author Information
Author(s): ME Gore, G Rustin, M Slevin, C Gallagher, R Penson, R Osborne, J Ledermann, T Cameron, JM Thompson
Primary Institution: Royal Marsden Hospital
Hypothesis
Single-agent paclitaxel will be effective in patients with previously untreated stage IV epithelial ovarian cancer.
Conclusion
High-dose paclitaxel is active and well tolerated in patients with stage IV epithelial ovarian cancer.
Supporting Evidence
- One patient had a complete response and 12 patients had partial responses.
- The overall response rate was 39.4%.
- The median survival of patients was 17.2 months.
- Neutropenia was the main toxicity encountered, with 31% of patients experiencing grade 3 and 19% grade 4.
- 78% of patients experienced noticeable alopecia.
Takeaway
This study tested a medicine called paclitaxel on patients with a serious type of cancer, and it helped some of them feel better for a while.
Methodology
Patients received paclitaxel intravenously at a dose of 225 mg/m² on a 21-day cycle for six courses.
Potential Biases
Selection bias may have occurred due to including only patients with good performance status.
Limitations
The study included only patients with measurable disease, which may not represent all patients with stage IV cancer.
Participant Demographics
Median age of participants was 57 years, with a range of 20-73 years.
Statistical Information
Confidence Interval
95% CI 23-58%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website